Intensity therapeutics, inc. and the swiss group for clinical cancer research sakk receive european medicines agency authorization to initiate phase 2 invincible-4 (sakk/66/22) study for int230-6 in the treatment of presurgical triple-negative breast cancer in france

Invincible-4 (sakk/66/22) study continues to recruit patients in eight sites in switzerland shelton, conn. and bern, switzerland , may 6, 2025 /prnewswire/ -- intensity therapeutics, inc. (nasdaq: ints), ("intensity" or "the company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, and the swiss group for clinical cancer research sakk ("sakk"), a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major swiss hospitals since 1965, announced that the european medicines agency ("ema") has authorized the initiation of the invincible-4 (sakk 66/22) ("invincible-4 study") (nct06358573) in france in collaboration with unicancer.
INT Ratings Summary
INT Quant Ranking